Cancer and Leukemia Group B
癌症和白血病 B 组
基本信息
- 批准号:7892673
- 负责人:
- 金额:$ 20.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-06-01 至 2010-03-31
- 项目状态:已结题
- 来源:
- 关键词:18 year oldAcademic Medical CentersAchievementAcute leukemiaAddressAdjuvantAdjuvant ChemotherapyAdjuvant TherapyAdolescentAdoptedAdverse eventAdvisory CommitteesAdvocateAffectAfrican AmericanAgeAllogenicAm 580American College of Radiology Imaging NetworkAmerican Society of Clinical OncologyAncillary StudyAntibodiesAntineoplastic AgentsApplications GrantsArchivesAreaArsenic TrioxideArtsAttentionAutologousAutologous Stem Cell TransplantationAwardAzacitidineBCL2 geneBasic ScienceBehavioral SciencesBiologicalBiological AssayBiological MarkersBiological MarkersBiological ProductsBiologically Based TherapyBiologyBone DensityBone Marrow TransplantationBreastBreast Cancer PreventionBudgetsBusulfanCD3 AntigensCaliforniaCancer BiologyCancer ControlCancer PatientCancer SurvivorCancer and Leukemia Group BCandidate Disease GeneCaregiversCaringCategoriesCell TransplantsCellsCertificationChairpersonCharacteristicsChemotherapy-Oncologic ProcedureChestChicagoChildren&aposs Oncology GroupChimerismCisplatinClassificationClinicalClinical PharmacologyClinical ResearchClinical Research AssociateClinical TrialsClinical Trials Cooperative GroupClinical Trials Data Monitoring CommitteesClinical Trials DesignClinical Trials NetworkCollaborationsColon CarcinomaColorectal CancerCommitCommittee MembersCommunicationCommunitiesCommunity Clinical Oncology ProgramCommunity HospitalsComorbidityCompanionsComplexComputer softwareConcept ReviewConsentControlled Clinical TrialsCore FacilityCorrelative StudyCounselingCredentialingCritiquesDNADNA Microarray ChipDataData AnalysesData CollectionData SetDatabasesDependencyDevelopmentDiagnosisDiagnosticDisciplineDiscipline of NursingDiseaseDisease remissionDisease-Free SurvivalDisorder by SiteDocumentationDoseDrug EvaluationDrug FormulationsDrug IndustryDrug KineticsDrug resistanceDysmyelopoietic SyndromesERBB2 geneEarly DiagnosisEastern Cooperative Oncology GroupEconomicsEducationElderlyElementsEligibility DeterminationEnrollmentEnsureEnzymesEpidemiologyEquilibriumEsophagealEthnic groupEvaluationEventEvolutionExhibitsFaceFacultyFeedbackFollicular LymphomaFosteringFreezingFunctional disorderFundingFutureGenerationsGenesGenetic PolymorphismGenitourinary systemGeriatric AssessmentGoalsGrantGroup ProcessesHealthHealth ServicesHealthcareHematopoieticHispanicsHistologyHodgkin DiseaseHomologous TransplantationHospitalsHourHuman ResourcesImageImaging technologyImmuneImmunophenotypingIncidenceIndividualInferiorInstitutesInstitutionInternationalInterventionInvestigational New Drug ApplicationKidneyKnowledgeLaboratoriesLaboratory StudyLatinoLeadLeadershipLearningLengthLibrariesLinkLiving CostsLocationLungLymphedemaLymphographyLymphomaMagnetic Resonance ImagingMaintenanceMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of pancreasMalignant neoplasm of prostateMalignant neoplasm of testisMalignant neoplasm of urinary bladderManuscriptsMaximum Tolerated DoseMeasurementMedicalMedical OncologistMedicineMentorsMesotheliomaMethodologyMicrometastasisMicroscopyMinorityMissionModalityModelingMolecularMolecular AnalysisMolecular CytogeneticsMolecular ProfilingMolecular TargetMonitorMonoclonal AntibodiesMonoclonal Antibody TherapyMorbidity - disease rateMultiple MyelomaMutationNCI Board of Scientific AdvisorsNamesNatural HistoryNelarabineNeoadjuvant TherapyNephrectomyNew AgentsNewly DiagnosedNon-Small-Cell Lung CarcinomaNorth CarolinaNorth Central Cancer Treatment GroupNursesNursing SocietiesObservational StudyOffice for Human Research ProtectionsOhioOncologic NursingOncology NurseOnline SystemsOperative Surgical ProceduresOralOrganOutcomeP-GlycoproteinP-GlycoproteinsPET/CT scanPaclitaxelPainPaperParaffin EmbeddingParticipantPathologistPathologyPatient CarePatient Outcomes AssessmentsPatient RecruitmentsPatientsPatternPeer ReviewPelvisPerformancePeripheral Nervous System DiseasesPersonal SatisfactionPharmaceutical PreparationsPharmacistsPharmacodynamicsPharmacogeneticsPharmacogenomicsPharmacologyPhasePhase I Clinical TrialsPhase I/II TrialPhase II Clinical TrialsPhase III Clinical TrialsPhysiciansPilot ProjectsPlasmaPlayPoliciesPopulationPopulation SciencesPositioning AttributePositron-Emission TomographyPostdoctoral FellowPreparationPreventionPreventive InterventionPrincipal InvestigatorProceduresProcessProductivityPrognostic MarkerProstateProteinsProtocols documentationPublicationsPublishingPulmonologyQualifyingQuality ControlQuality of lifeRadiation OncologistRadiation OncologyRadiation therapyRadiology SpecialtyRandomized Clinical TrialsRandomized Controlled Clinical TrialsRecommendationRecording of previous eventsRecordsRecruitment ActivityRecurrent diseaseRegulatory AffairsRelapseRelative (related person)Renal Cell CarcinomaRenal carcinomaReportingRequest for ApplicationsResearchResearch ActivityResearch DesignResearch Ethics CommitteesResearch InfrastructureResearch PersonnelResearch Project GrantsResidual NeoplasmResistanceResourcesRevlimidRiskRoleSafetySample SizeSamplingSan FranciscoScheduleScienceScientistSeasonsSecureSeriesServicesSignal PathwaySiteSite VisitSocial AdjustmentSolidSolid NeoplasmSouthwest Oncology GroupSpecific qualifier valueStagingStem cellsStructureSupportive careSurface AntigensSurgeonSurgical OncologySurveysSurvival RateSurvivorsSymptomsSystemSystemic TherapyT-LymphocyteTamoxifenTechniquesTechnologyTelephoneTestingTherapeuticTherapeutic IndexTherapeutic StudiesTherapeutics CommitteeTherapy Clinical TrialsThoracic Surgical ProceduresTimeTissue BankingTissue BanksTissue SampleTissuesToxic effectTrainingTraining ActivityTranslational ResearchTranslational Research Working GroupTransplantationTrastuzumabTravelTreatment EfficacyTreatment ProtocolsTreatment outcomeTriageTumor AngiogenesisTumor BiologyTumor MarkersTumor TissueUncertaintyUnderrepresented MinorityUnderserved PopulationUnited StatesUniversitiesUniversity of Chicago Cancer Research CenterUpdateUpper armUrineUrogenital CancerUrologyVascular Endothelial Growth FactorsVeteransVisionWomanWorkWritingZoledronic Acidabstractingadvanced diseaseage groupanticancer researchbasebevacizumabbiobankbisphosphonatebladder Carcinomabreast lumpectomybreast surgerycancer carecancer imagingcancer preventioncancer surgerycancer therapycancer typecapecitabinecareercell killingchemotherapychronic graft versus host diseaseclinical practiceconditioningcooperative studycostcost effectivenessdata collection methodologydesigndisease characteristicdrug developmentevidence baseexperiencefallsfunctional outcomesgastrointestinalgemcitabinegenome-widegraft vs host diseasehealth related quality of lifehigh riskhormone therapyhuman subject protectionimprovedinhibitor/antagonistinnovationinsightinterdisciplinary approachinterestirinotecankidney cellleukemialeukemia/lymphomamalignant breast neoplasmmeetingsmemberminimally invasivemolecular imagingmortalitymultidisciplinarynamed groupneoplasm registryneoplasm resourceneoplastic cellnew technologynovelnovel strategiesnovel therapeuticsnursing interventionolder patientolder womenoncologyorganizational structureoutcome forecastpatient populationpopulation basedpreventprofessorprogesterone 11-hemisuccinate-(2-iodohistamine)programsprotocol developmentquality assuranceradiologistresearch clinical testingrespiratoryresponseskillssmall moleculestandard carestandard of carestatistical centerstemsuccesssurvivorshipsymptom managementtechnology/techniquetime usetooltransmission processtreatment responsetreatment strategytreatment trialtrial comparingtumortumor progressionurinary gonadotropin fragmentvirtualworking groupyoung adult
项目摘要
DESCRIPTION (Provided by applicant): The CALGB is comprised of 26 academic medical centers and over 200 affiliated community hospitals joined in the pursuit of improved cancer treatment and better understanding of tumor biology and cancer treatment outcomes via the conduct of controlled clinical trials. Over 4,000 members of the Group including oncology physicians, radiologists, pathologists, statisticians, clinical research associates, oncology nurses, pharmacists, health outcomes researchers, and basic scientists participate in these studies. From 25-30 phase III protocols are active at any one time, along with phase II and phase I studies that provide preliminary data required for the appropriate design of large scale randomized trials. Multidisciplinary disease committees of the Group design and implement protocols for the treatment of patients with leukemia, lymphoma, breast, respiratory, Gl and GU cancer. Modality committees, including Leukemia Correlative Sciences, Imaging, Pharmacology and Experimental Therapeutics, Surgery, Transplant, Cancer in the Elderly, Cancer Control and Health Outcomes, and Oncology Nursing provide expertise that enhances the contribution of these disciplines to CALGB studies. Scientific resources committees, including Clinical Research Associates, Pathology and Radiation Oncology, provide essential quality assurance and training activities for the Group. Major areas of emphasis in CALGB include development of innovative treatments for patients with cancer; studies of molecular predictors of prognosis and response to therapy; studies of the pharmacokinetics, pharmacodynamics and pharmacogenetics of new and established anticancer drugs; evaluation of minimally invasive surgical techniques and novel imaging technologies; determining the cost and cost-effectiveness of new cancer therapies; evaluating the impact of cancer and its treatment on the quality of life of cancer patients and their caregivers; developing new strategies for cancer prevention; and addressing the needs of special populations, particularly minorities and the elderly. A new core facility in cancer imaging was established to provide central review and archiving of PET and CT images and to set standards for image acquisition and transmission at CALGB institutions. Three new molecular reference laboratories are proposed in this application to provide biomarker assessments that are necessary to determine patient eligibility or treatment assignment in CALGB studies of targeted therapies. Three established biorepositories collect, archive and distribute frozen and paraffin-embedded solid tumor tissues, leukemia cells, plasma, serum, urine and DNA for correlative science studies.
CALGB由26个学术医疗中心和200多家附属社区医院组成,通过开展对照临床试验,共同追求改善癌症治疗,更好地了解肿瘤生物学和癌症治疗结果。超过4,000名小组成员,包括肿瘤学医生,放射学家,病理学家,统计学家,临床研究助理,肿瘤学护士,药剂师,健康结果研究人员和基础科学家参加了这些研究。从25-30 III期方案是活跃在任何一个时间,沿着与II期和I期研究,提供所需的初步数据,适当的设计大规模随机试验。本集团的多学科疾病委员会设计并实施治疗白血病、淋巴瘤、乳腺癌、呼吸道癌、GI和GU癌症患者的方案。模态委员会,包括白血病相关科学,成像,药理学和实验治疗,外科手术,移植,老年人癌症,癌症控制和健康结果,以及肿瘤护理提供专业知识,提高这些学科对CALGB研究的贡献。科学资源委员会,包括临床研究助理、病理学和放射肿瘤学,为本集团提供必要的质量保证和培训活动。CALGB的主要重点领域包括开发癌症患者的创新治疗方法;预后和治疗反应的分子预测因子研究;新的和已建立的抗癌药物的药代动力学,药效学和药物遗传学研究;评估微创手术技术和新的成像技术;确定新的癌症治疗方法的成本和成本效益;评估癌症及其治疗对癌症患者及其照顾者生活质量的影响;制定预防癌症的新战略;满足特殊人群,特别是少数群体和老年人的需要。建立了一个新的癌症成像核心设施,以提供PET和CT图像的中央审查和存档,并为CALGB机构的图像采集和传输制定标准。本申请中提出了三个新的分子参考实验室,以提供生物标志物评估,这对于确定靶向治疗CALGB研究中的患者资格或治疗分配是必要的。三个已建立的生物储存库收集、存档和分发冷冻和石蜡包埋的实体肿瘤组织、白血病细胞、血浆、血清、尿液和DNA,用于相关科学研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD L SCHILSKY其他文献
RICHARD L SCHILSKY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD L SCHILSKY', 18)}}的其他基金
Cancer and Leukemia Group B Human Specimen Repositories
癌症和白血病 B 组人类样本库
- 批准号:
7074058 - 财政年份:2005
- 资助金额:
$ 20.14万 - 项目类别:
Cancer and Leukemia Group B Human Specimen Repositories
癌症和白血病 B 组人类样本库
- 批准号:
7218023 - 财政年份:2005
- 资助金额:
$ 20.14万 - 项目类别:
Cancer and Leukemia Group B Human Specimen Repositories
癌症和白血病 B 组人类样本库
- 批准号:
6930205 - 财政年份:2005
- 资助金额:
$ 20.14万 - 项目类别:
Cancer and Leukemia Group B Human Specimen Repositories
癌症和白血病 B 组人类样本库
- 批准号:
7394411 - 财政年份:2005
- 资助金额:
$ 20.14万 - 项目类别:
Cancer and Leukemia Group B Human Specimen Repositories
癌症和白血病 B 组人类样本库
- 批准号:
7596998 - 财政年份:2005
- 资助金额:
$ 20.14万 - 项目类别:
CALGB STUDIES OF BREAST CANCER IN THE ELDERLY
CALGB 对老年人乳腺癌的研究
- 批准号:
6649265 - 财政年份:2000
- 资助金额:
$ 20.14万 - 项目类别:
CALGB STUDIES OF BREAST CANCER IN THE ELDERLY
CALGB 对老年人乳腺癌的研究
- 批准号:
6792574 - 财政年份:2000
- 资助金额:
$ 20.14万 - 项目类别:
CALGB STUDIES OF BREAST CANCER IN THE ELDERLY
CALGB 对老年人乳腺癌的研究
- 批准号:
6377817 - 财政年份:2000
- 资助金额:
$ 20.14万 - 项目类别:
CALGB STUDIES OF BREAST CANCER IN THE ELDERLY
CALGB 对老年人乳腺癌的研究
- 批准号:
6292671 - 财政年份:2000
- 资助金额:
$ 20.14万 - 项目类别:
相似海外基金
Building a Systems Approach to Community Health and Health Equity for Academic Medical Centers
为学术医疗中心建立社区健康和健康公平的系统方法
- 批准号:
9212055 - 财政年份:2016
- 资助金额:
$ 20.14万 - 项目类别:
Building a Systems Approach to Community Health and Health Equity for Academic Medical Centers
为学术医疗中心建立社区健康和健康公平的系统方法
- 批准号:
9348616 - 财政年份:2016
- 资助金额:
$ 20.14万 - 项目类别:
A CONFERENCE ON THE 'CRISIS' OF ACADEMIC MEDICAL CENTERS
关于学术医疗中心“危机”的会议
- 批准号:
6335654 - 财政年份:2000
- 资助金额:
$ 20.14万 - 项目类别: